Recent Updates
Recently added Catalysts

Gefitinib or Docetaxel

Phase 3

Non-Small Cell Lung Cancer | Small molecule | Oncology |AstraZeneca PLC|Last Updated: Dec 18, 2007

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment484

FDA Designations

No designations recorded

Clinical trial landscape

Gefitinib or Docetaxel · 1 trial · 1 indication

Phase 3 1
NCT00252707Iressa 2nd Line Phase III Study in JapanNon-Small Cell Lung Cancer
COMPLETED484 Analytics
PHASE3COMPLETED
Iressa 2nd Line Phase III Study in Japan
Non-Small Cell Lung Cancer
NCT00252707484
Unlock trial analytics

Study Endpoints

Primary Endpoints

Determine the overall survival with these treatments as the primary outcome.

Secondary Endpoints

Determine the followings as the secondary outcome variables:
- Progression-free survival (PFS)
- Time to treatment failure (TTF)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
Gefitinib or DocetaxelDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites40

Inclusion Criteria: * You are "histologically" or "cytologically" confirmed to have recurrent or metastatic NSCLC * You have been treated with chemotherapy including platinums for NSCLC. Exclusion Criteria: * You have received treatment for non-small lung cancer within 4 weeks before your partici...

Countries:Japan
Unlock Eligibility Criteria

Competitive Landscape -Non-Small Cell Lung Cancer 387 trials

Top 20 of 83 competitors

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK24PHASE3Pembrolizumab, Olaparib, Etoposide, Carboplatin, Cisplatin
AstraZeneca PLCAZN62PHASE3Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin
Revolution Medicines, Inc.RVMD8PHASE3daraxonrasib, docetaxel
Eli Lilly and CompanyLLY18PHASE3Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
AbbVie, Inc.ABBV10PHASE3Telisotuzumab Vedotin, Docetaxel
Bristol-Myers Squibb CompanyBMY18PHASE3Repotrectinib, Crizotinib
BioNTech SE Sponsored ADRBNTX7PHASE3Gotistobart, Docetaxel
Gilead Sciences, Inc.GILD4PHASE3Sacituzumab Govitecan-hziy, Docetaxel
Pfizer Inc.PFE16PHASE3Lorlatinib, Crizotinib
Johnson & JohnsonJNJ17PHASE3Lazertinib, Amivantamab, Pemetrexed, Carboplatin
ArriVent BioPharma, Inc.AVBP9PHASE3Firmonertinib
Amgen Inc.AMGN4PHASE3ABP 234, Pembrolizumab
Novartis AG Sponsored ADRNVS9PHASE3JDQ443, docetaxel
GSK plc Sponsored ADRGSK3PHASE3Dostarlimab, Belrestotug, Pembrolizumab
Summit Therapeutics IncSMMT2PHASE3Ivonescimab, Pembrolizumab
Nuvation Bio, Inc. Class ANUVB4PHASE3Taletrectinib, Crizotinib
Genmab A/S Sponsored ADRGMAB4PHASE3Acasunlimab, Pembrolizumab, Docetaxel
Regeneron Pharmaceuticals, Inc.REGN6PHASE2Cemiplimab, Platinum-based chemotherapy, REGN7075
BeOne Medicines Ltd. Sponsored ADRONC6PHASE3Tislelizumab, Cisplatin, Paclitaxel, Pemetrexed Disodium, Carboplatin
BeyondSpring Inc.BYSI1PHASE3Plinabulin, Docetaxel
Unlock Competitive Intelligence